百花医药:2025一季报净利润0.21亿 同比下降0%

Financial Data and Indicators - The basic earnings per share for Q1 2025 is 0.0540 yuan, showing a slight decrease of 0.18% compared to Q1 2024, which was 0.0541 yuan [1] - The net asset per share increased by 6.28% to 2.03 yuan in Q1 2025 from 1.91 yuan in Q1 2024 [1] - The operating revenue for Q1 2025 reached 0.97 billion yuan, reflecting a growth of 6.59% compared to 0.91 billion yuan in Q1 2024 [1] - The net profit remained stable at 0.21 billion yuan for both Q1 2025 and Q1 2024 [1] - The return on equity decreased to 2.69% in Q1 2025 from 2.88% in Q1 2024, a decline of 6.6% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 14,134.65 million shares, accounting for 36.8% of the circulating shares, with a decrease of 567,500 shares compared to the previous period [1] - The largest shareholder, 米在齐, holds 3,455.94 million shares, representing 9.00% of the total share capital, with no change [2] - 新疆生产建设兵团投资有限责任公司 holds 444.35 million shares, accounting for 1.16% of the total, with no change [2] - 新进 shareholder, 新疆兵设物产管理有限责任公司, holds 357.21 million shares, representing 0.93% of the total [2] Dividend Distribution - The company has decided not to distribute dividends or transfer shares this time [3]